Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aside from all the noise/nonsense/silliness here, INMG is a favorite OTC play/opportunity.
The market will determine INMG's movement, and INMG's ability to develop Cannanet.tv. I don't care if you're long, short, MM, flippers...I'm still adding at prices I'm comfortable with. I haven't sold any, and don't plan on selling in the near future.
Of the 20 or so different INMG purchases I've made, I may have slapped the ask 2 or 3 times, when I felt like it may have been the only way for me to get the buy I wanted...simple as that...The market commanded it.
SR does have a good point about shaking up the MM's, and not letting them dictate the price action, and protecting your position.
I prefer to let INMG and their progress do the talking/action, and believe fair value price action will follow....as INMG and the market dictates it.
To each their own. Some strategies will pay off, other strategies will pay off a lot more and some strategies will get crushed.
GLTA
I guess that's the difference between you and me. I know what I'm buying.
I'm not looking for short term profit here, I'm a holder...and a very strong holder.
Good luck to you.
Major support came in @ .28 & .30 today....great bounce and reversal.
Looking forward to next week...as we get closer to new contracts, 10Q filings, statement from Johnan, squeeze out the rest of the shorts...etc...the list of catalysts goes on and on.
I would not want to be short into next week. And I can't believe the flippers here, no clue what they own.
All, Have a great weekend!
Who's ready for TMPS's Market Cap to explode to it's Fair Value....$75M+
I got my popcorn ready...lol
Yes Sir,
Recommend going back to their posts from last night and this morning....lots of significant info/dd....i thing many just glossed over....GL...partly why I added 50k shares this morning...got some .28 in there too...more orders in ready.
Thank you Bill & Qtrader
INFO from BillJay & QTrader
The new entity "Tempus Jets N149LP, LLC" found by BillJay was created on 7/27/17 by going to this website.
https://icis.corp.delaware.gov/Ecorp/EntitySearch/NameSearch.aspx
That N149LP jet was test flown on 7/9/17. Test flown around southern FL for 50 min according to this link. So that supports speculation of its sale. To whom? It's got to be Tempus Jets?
http://flightaware.com/live/flight/N149LP
It appears TMPS has---or is about to--- purchase this jet from it's owner, HIDECA USA, INC. The selling price was $7.9 mil. (A new one costs $45 mil.) Not sure of payment terms. In the "Subsequents Event" section of the upcoming 10Q in August terms of the sale should be disclosed and perhaps its purpose.
* Hopefully, a PR or Update will be released shortly to give further details. The jet accommodates 13 passengers.
Has anyone seen Tom today?...lol
Relax....INMG will make it's move soon
Would not want to be holding short shares into the weekend with all this behind the scenes going down.
New entity create 7/27/17....TMPS has several things to share with Investors....and it can happen at anytime...IR lady says update coming....10Q coming....Johan's Statement coming.....It is all coming any day now
I agree. Looks like there was a major effort to walk down the price @ 12:40 (lunch) on a Friday afternoon....The 140K shares trade @ .28, now no more pressure...I think we go up from here...potentially close green too.
GLTA
The High Times Deal looks to be a good investment for MSRT.
See article from new cannabis ventures today:
https://www.newcannabisventures.com/high-times-headed-to-the-nasdaq/
I think it will help them down the road, I'm sure MSRT, KSHB, and other involved in the deal will use it to help leverage their businesses too.
GLTA
Could be big reversal coming
Keep the shares coming at these prices
Welcome Capt.
GLTY
I say we should squash it, and buy back in if you see the value in INMG. Can't complain buying in the 009/01 range...you know there's great potential here.
Not many tickers come close to INMG in OTC land.
GLTA
Well, there's certainly a good chance we'll see a little for the stake in Night Flight, but I don't think it will be dramatic.
We are also expecting to have to raise a little bit of capital, as it states in filings, for the building and development of Cannanet.tv.
I highly doubt we will see huge dilution, given our CEO owns ~100M Shares. Tom isn't going to shoot himself in the foot, or do some sort of huge dilution without good cause.
That's a huge reason why I feel comfortable getting behind INMG. The CEO's interest are aligned with their investors interest.
Tough to find in OTC Land.
GLTA
Pay attention to SR's post, and look at the value Night Flight brings to the table.
I underestimated the Night Flight deal, but this is huge.
Night Flight is offered/streamed on Roku, Apple TV, Chromecast & Amazon Fire.
Start connecting the dots, and the potential story being told here. Night Flight alone should have added $4-5M to INMG's small market cap of only ~$2M.
Night Flight minority interest = Sweet Heart Deal.
GLTA
Can't believe my .003's didn't get filled today, and Tom's no where to be found?
LOL
Has anyone seen Tom today? Where is Tom? Is Tom on vacation?
LOL
I'm still waiting to hear from those who are claiming massive dilution here??????
I want to know how your arriving at those conclusions???
WHY???????
Exactly, we have to wait for the filings.
The CEO Tom owning about ~ 100M shares, do you think he is going to do something irresponsible with shares?....Do you think he's going to screw himself over????
Dilution INMG is total nonsense....BS
Tom will use capital structure as he see fit to grow INMG......Again, Someone explain to me why Tom would ever dilute his own shares, if he didn't think it was a good business decision for the long term growth of INMG?????
WHY??????
Exactly my point about MSRT CEO.
Richard Branson ....respects him enough to hang and take pictures with him.
I could care less if he smokes, or if he's taken 300 bong rips before that picture....
So I repeat, many are under-estimating MSRT CEO...Time will tell...just my take.
GLTA
I don't believe they are diluting substantial shares. I believe some shares were added for the night flight deal.
In reality INMG may need to raise capital for the costs associated with Cannanet.tv(In filings), but no one is sure how much, or if a good portion of these cost are affordable with current earnings? INMG has had a profitable business for the past several Q's.
Like I continue to state...I'm putting my money on Tom and INMG, until they give me a reason to change my mind, which I don't expect...but I could be wrong.
I believe investors have an opportunity to buy cheap shares at current levels....could it go lower....yes...and I would accumulate more...IMO
GLTA
Great picture!...Who is the guy on the right?
I'm not sure if there's many short shares?...just investors who are lacking confidence in what they own.
What is Tom up to today?...I heard he's out of the office. Where is he? Is he working on INMG? Is he at the beach with SR...lol
GLTA
Who is seriously selling in the low 30's today?
Folks who don't have a clue what they own, IMO.
GLTA
I don't disagree, but I see some value here...CEO smarter than many give him credit for...time will tell
GLTA
It's already late afternoon and PGAS is finally waking up for the day.
Consolidation, type of ticker that may surprise investors here...even though they haven't capitalized on the app/platform...it's a mighty nice asset that will require patience before they're able to unlock it's value.
Compliance is a big deal in a fast growing market. And you know the state oversight will be lined up for their piece(Taxes/Fines..etc), big time money maker for all involved.
I'm buying on weakness.
GLTA
The suspense! INMG has everyone on edge....lol
Added some more diluted shares today...lol
GLTA
I'm with you on that.
Holding tight and adding occasionally.
Okay, I guess I just have a much longer term view than the week or two the CEO might be out of the office. I'm not worried about short term pps in this range, because in 3-6 months...no one who owns INMG here, or at .02+ will be underwater.
I prefer the CEO to be out of the office. I doubt he's on vacation with the amount of work INMG has going on now. He's launching a Streaming channel in 2-3 months, with soft launch/preview at MJAC Sept 1st, deals and progress don't happen with him sitting at his desk twiddling his thumbs.
Patience INMG'ers...Patience....price action has been fine....of course we'd love to see it higher, but I'm fine with how it's consolidating.
GLTA
Silly reasoning. So what if he's out of the office....means nothing.
So far, is still up nicely over the past couple of weeks and bouncing off 50 day.
I doubt major price action today. Just an article of a study in Europe IMLFF emailed out to their subscribers, but great to see their work is progressing.
GLTA
InMed Announces Publication in European Journal of Pain
July 27, 2017
Vancouver, BC – July 27, 2017 - InMed Pharmaceuticals, Inc. (“InMed” or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the publication of company-sponsored research in the European Journal of Pain. The article, titled “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation”, presents results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship program. The study was conducted by Dr. Hayes Wong and Prof. Brian Cairns at the University of British Columbia and was co-authored by Dr. Sazzad Hossain, Chief Scientific Officer of InMed.
The study results suggest that peripheral application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) may provide a valuable approach in treating severe pain. The model utilized in this study mimics muscle pain reported by sufferers of temporomandibular disorders (TMD) that affect the jaw muscles and joint. TMD is a chronic pain condition that is difficult to treat with current pain-relieving medications and more commonly affects women than men.
“Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the ‘holy grails’ in the field of analgesia”, said Dr. Sazzad Hossain, CSO of InMed. “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”
Use of InMed’s proprietary bioinformatics database assessment tool has led to the identification of several individual cannabinoid compounds, or combinations thereof, to specifically address both chronic and acute pain in a topically-applied product. “InMed’s internal targeting capabilities, linking specific cannabinoids to diseases with a high unmet medical need, remains a fundamental component to our ongoing success in validating the role of this class of compounds in a wide range of diseases”, added Dr. Hossain.
For additional information, please follow this link to the article: http://onlinelibrary.wiley.com/doi/10.1002/ejp.1085/full
About Mitacs
Mitacs Elevate helps organizations develop their research & development management capacity in-house with a minimal impact on their R&D budgets. By connecting companies with a talented PhD graduates, the two-year research project encourages knowledge transfer of the fellow’s practical and professional skills to the organization. These collaborations help build research and development management capacity and companies benefit from fellows’ creativity and fresh approach to current research challenges.
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Contact: InMed Pharmaceuticals Inc .
Chris Bogart
Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: that peripheral or topical application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) provides a valuable approach in treating chronic and/or acute severe pain without central side effects, InMed’s proprietary bioinformatics database assessment tool, linking specific cannabinoids to diseases with a high unmet medical need, being able to validate the role of this class of compounds in a wide range of diseases, and the expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: that peripheral or topical application of cannabinoids, identified by InMed’s proprietary bioinformatics database assessment tool, will be able to effectively target the natural endocannabinoid receptor system (in this case, receptor CB1) which will provide a valuable approach in treating chronic and/or acute severe pain without central side effects; InMed’s proprietary platform technology, product pipeline and drug development programs may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com . In addition, readers should review the disclosure under the heading “Risk Factors” in the Final Prospectus, once filed. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Nice, thanks for sharing.
Hopefully you're enjoying the vacation.
GLTA
Nice posts Houdini.
OTC Short Report: This is what I see.
http://otcshortreport.com/?index=INMG&action=view
I don't really care how many shares are short. Makes for a healthy trading environment...but we're not $25M short
If someone were $25M shares short, they would need $2.50/per share to back that trade. $62,000,000....who in their right mind would put that sort of capital up, to short a penny stock....highly doubtful...nothing but BS....nothing but noise....etc...etc
I'm not sure why you think they are currently short 25M shares now, SR said "25M+ SHARES when the announced CANNANET.TV".....when cannanet.tv was acquired in April 2017. That's what SR said this morning.
He did not say 25M short for today.
Here's what the OTC Short report says. See link below. This gets updated twice a month, so new update coming soon.
http://otcshortreport.com/?index=INMG&action=view
Exactly, INMG not worth $1.00. Is it possible, Yes.
How will it get there, we ask? REVENUES from Cannanet.tv, INMG reaches a $1.00 when their concept/plan is producing substantial revenue and profits(12-24 months).
Is $.10 to $.15 Possible? Yes, in the short run (3-6 months) if Cannanet.tv is progressed along nicely, and we can see a path to solid revenues.
Could we see $.02 to $.05 shortly, leading up to MJAC...Yes, but we'll need a catalyst other than MJAC is coming. I think the probability is higher we'll hear something out of INMG before MJAC, but we can't be 100% sure either.
GLTA
Agreed.
Although, Night Flight Deal recently occurred.
The probability of Cannanet.tv is higher, INMG doesn't make a deal in the streaming space, if they're not making strides to develop their business in that area.
Deals don't happen overnight. Lot's work to be done to prepare for MJAC if they're doing a soft beta launch at MJAC Sept 1 & 2. So we have to be patient, which is tough to come by in OTC land.
Other pieces of the puzzle are still in the works and the Q is expected soon.
Clearly, the Mary Jane festival was over-hyped, as to expect something major to happen, but I don't recall Tom ever promising anything from it? The festival was hyped up on IHUB, that's it.
INMG has never been much of a PR company. I don't expect things to change in that regard either. INMG does the majority of their
communication through their filings & their #'s, which have looked healthy for the last several quarters. That's requires patience to hold.
With everything I know, I still believe INMG is worth $8M-12M market cap versus the ~ $2.5M it's at now.
But your points are well taken, and offer a realistic perspective....which is positive for this board.
Thank you
They don't realize it yet...but they'll need to buy them sooner rather than later.
GLTA